Company intelligence / Profile preview

CytoVac

Hørsholm, N/A, Denmarkcytovac.com ↗

Ownership: Private
Employees: ~49
Development stage: Phase 1

Overview

CytoVac has developed the ALECSAT platform—a cell-based immunotherapy using a patient’s own activated immune cells to target tumors. The approach aims to minimize side effects compared to traditional therapies. The company has reported promising preclinical and early clinical results but discontinued its glioblastoma program; further development appears focused on next-generation products targeting other cancers such as breast cancer

Therapeutic areas: Oncology
Modalities: Cell therapy (autologous activated immune cells)immunotherapy
Industry: Biotech

Drug pipeline

1 asset

alecsat

Beyond the preview

Go deeper on CytoVac.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoVac.

Explore the full profile